HLAMatchmaker-defined triplet matching is not associated with better survival rates of patients with class I HLA allele mismatched hematopoietic cell transplants from unrelated donors. Biol Blood Marrow Transplant 2008 Sep;14(9):1064-1071
Date
08/30/2008Pubmed ID
18721770Pubmed Central ID
PMC2572684DOI
10.1016/j.bbmt.2008.07.001Scopus ID
2-s2.0-49449086957 (requires institutional sign-in at Scopus site) 36 CitationsAbstract
This report addresses the concept that permissible HLA mismatching, that is, mismatches that do not generate an allogeneic response, in hematopoietic stem cell transplantation (HCT) can be determined with structural similarity of polymorphic regions. We have applied the triplet version of a structural algorithm called HLAMatchmaker, which considers short sequences involving polymorphic amino acid residues on the molecular surface as key elements of immunogenic epitopes. The triplet matching effect was analyzed in a National Marrow Donor Program dataset consisting of 744 unrelated hematopoietic cell transplantation cases with 1 HLA-A, -B, or -C mismatch and 1690 fully HLA-A, -B, -C, -DR, or -DQ allele matched cases. In multivariate models adjusting for other significant clinical risk factors, the degree of triplet mismatching did not significantly correlate with patient survival, engraftment, or acute graft-versus-host disease (aGVHD). Other structurally based strategies should be pursued to identify permissible HLA mismatches in HCT.
Author List
Duquesnoy R, Spellman S, Haagenson M, Wang T, Horowitz MM, Oudshoorn MAuthors
Mary M. Horowitz MD, MS Professor in the Medicine department at Medical College of WisconsinTao Wang PhD Associate Professor in the Institute for Health and Equity department at Medical College of Wisconsin
MESH terms used to index this publication - Major topics in bold
Acute DiseaseAdolescent
Adult
Aged
Algorithms
Child
Child, Preschool
Databases, Factual
Disease-Free Survival
Donor Selection
Epitopes
Female
Graft Survival
Graft vs Host Disease
Hematologic Neoplasms
Histocompatibility Antigens Class I
Histocompatibility Testing
Humans
Infant
Living Donors
Male
Middle Aged
Retrospective Studies
Risk Factors
Survival Rate
